ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,569.99
      1.11%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. uniQure NV (QURE)

      7. uniQure NV (QURE) News

      QURE

      uniQure NV (QURE)

      uniQure NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:QURE
      DateTimeSourceHeadlineSymbolCompany
      11/07/20237:52AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
      11/07/20237:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      11/07/20237:05AMGlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
      10/27/202310:00AMPR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
      10/26/20232:38PMPR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
      10/26/20232:14PMPR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
      10/24/20237:05AMGlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
      10/06/20236:33AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
      10/06/20236:32AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QUREuniQure NV
      10/05/20234:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      10/05/20237:05AMGlobeNewswire Inc.uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage ProgramsNASDAQ:QUREuniQure NV
      10/02/20239:50PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      10/02/20237:05AMGlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
      09/20/20234:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      09/05/20231:59PMDow Jones NewsRe/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit From S&P SmallCap 600NASDAQ:QUREuniQure NV
      09/05/20237:05AMGlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
      09/01/20236:51PMPR Newswire (US)Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600NASDAQ:QUREuniQure NV
      08/01/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      08/01/20237:37AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
      08/01/20237:05AMGlobeNewswire Inc.uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
      07/12/20234:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      07/10/202310:58AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
      06/26/20237:11AMGlobeNewswire Inc.uniQure Announces Leadership Addition to Support Advancement of Clinical ProgramsNASDAQ:QUREuniQure NV
      06/22/20235:00PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QUREuniQure NV
      06/21/20237:05AMGlobeNewswire Inc.uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
      06/20/20235:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
      06/20/20235:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
      06/20/20235:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
      06/20/20235:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
      06/20/20235:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
       Showing the most relevant articles for your search:NASDAQ:QURE